Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide-Reference-Cited by-同舟云学术

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Published:2015-05-07 Issue:19 Volume:125 Page:3024-3031
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

McCurdy Shannon R.¹,Kanakry Jennifer A.¹,Showel Margaret M.¹,Tsai Hua-Ling¹,Bolaños-Meade Javier¹,Rosner Gary L.¹,Kanakry Christopher G.¹,Perica Karlo¹,Symons Heather J.¹,Brodsky Robert A.¹,Gladstone Douglas E.¹,Huff Carol Ann¹,Pratz Keith W.¹,Prince Gabrielle T.¹,Dezern Amy E.¹,Gojo Ivana¹,Matsui William H.¹,Borrello Ivan¹,McDevitt Michael A.¹,Swinnen Lode J.¹,Smith B. Douglas¹,Levis Mark J.¹,Ambinder Richard F.¹,Luznik Leo¹,Jones Richard J.¹,Fuchs Ephraim J.¹,Kasamon Yvette L.¹

Affiliation:

1. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD

Abstract

Key Points Nonmyeloablative, related HLA-haploidentical BMT utilizing high-dose posttransplantation cyclophosphamide has a favorable safety profile. Risk-stratified relapse and survival outcomes with this approach are comparable to those of HLA-matched BMT.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/19/3024/1385228/3024.pdf

Reference35 articles.

1. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.;Brunstein;Blood,2011

2. Marrow transplantation from related donors other than HLA-identical siblings.;Beatty;N Engl J Med,1985

3. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.;Petersdorf;Blood,1998

4. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.;Morishima;Blood,2002

5. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.;Szydlo;J Clin Oncol,1997

Cited by 260 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HLA structure and function in hematopoietic-cell transplantation;Best Practice & Research Clinical Haematology;2024-09

2. Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;Bone Marrow Transplantation;2024-08-18

3. Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT;Blood Advances;2024-08-13

4. Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis;British Journal of Haematology;2024-08-04

5. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil;Transplantation and Cellular Therapy;2024-08